RNA Avidity Biosciences, Inc.: Operatsion marja

Avidity Biosciences, Inc. - RNA emitenti grafik logotipi

Avidity Biosciences (RNA) mushak patologiyalarini davolovchi dori vositalariga uzoq muddatli talabni ta'minlovchi maqsadli RNA terapiyalarini ishlab chiqadi. Biroq, daromadning yo'qligi va yuqori R&D xarajatlari kompaniyani klinik sinovlarga bog'liq qilib qo'ygan. AOC texnologiyalarining innovatsion salohiyati operatsion marja vaqtlar ketma-ketligi bilan tasdiqlanadi, bunda qiymat -194.80 darajasida qolmoqda, bu esa biznes modelining joriy holatini anglatadi.

aviditybiosciences.com (RNA): Operatsion foyda bo'yicha sotuv rentabelligi 04.07.2022dan 19.11.2026gacha

aviditybiosciences.com (RNA) kompaniyasi koʻrsatkichlari kesimi va tahlili

- aksiya narxi va baholash bo'yicha konsensus prognoz:
- kompaniya aksiyalari kapitallashuvi ma'lumotlari:
Kompaniyaning dastlabki tahlili:RNA, Avidity
Avidity Biosciences tayyor mahsulotlari

Avidity Biosciences (RNA) uchun operatsion samaradorlik darajasi geosiyosiy xavflar va xorijiy bozorlarda RNA asosidagi dori vositalarini ro'yxatdan o'tkazishning murakkabliklari sharoitida foyda keltirish qobiliyatini aks ettiradi. Ushbu ko'rsatkich operatsion foydaning tushumga nisbati sifatida hisoblanadi va barcha ishlab chiqarish xarajatlari chegirib tashlanganidan keyin, ammo soliqlar va foizlardan oldingi daromad ulushini o'lchaydi, bu esa kompaniyaning fundamental kapital barqarorligini ob'ektiv baholash imkonini beradi.

Avidity Biosciences raqobatchilari tahlili

Sotuvning operatsion marjasi TEM|QGEN - Operatsion foyda bo'yicha marjinallik|Operatsion marja IONS|RGEN - Sotuvning operatsion rentabelligi|crisprtx.com - Sotuvning operatsion marjasi|Operatsion foyda normasi WGS|RARE - Operatsion rentabellik|Beam Tx (BEAM) - Sotuvning operatsion marjasi|SRPT (Sarepta Therapeutics Inc) - Sotuvning operatsion marjasi|TWST: Operatsion foyda koeffitsiyenti|TXG (10xgenomics.com) - Operatsion marja|NTLA (Intellia Therapeutics, Inc.) - Operatsion foyda koeffitsiyenti|Operatsion rentabellik Stoke Corp (STOK)|Operatsion faoliyat rentabelligi BioLife|Operatsion marja WVE (Wave Life Sciences Ltd)|MAZE: Operatsion foyda bo'yicha sotuv rentabelligi|Sionna Therapeutics, Inc. - Operatsion marja|Operatsion foyda normasi PRME (Prime Medicine Inc)|TSHA (Taysha Gene Therapies, Inc.) - Sotuvning operatsion marjasi|QURE - Operatsion faoliyat rentabelligi|MGTX (MeiraGTx Corp) - Operatsion marja|Sotuvning operatsion rentabelligi REGENXBIO Inc. RGNX|Operatsion rentabellik Solid Biosciences (SLDB)|Ocugen Corp - Operatsion foyda bo'yicha sotuv rentabelligi|Operatsion rentabellik Pacific Biosciences PACB|Operatsion foyda koeffitsiyenti BNTC (Benitec)|Design Corp - Operatsion marja|Rocket Pharmaceuticals - Operatsion foyda koeffitsiyenti|Operatsion foyda bo'yicha sotuv rentabelligi 4D Molecular Therapeutics, Inc.|Sotuvning operatsion rentabelligi Lexeo Therapeutics (LXEO)|KRRO (Korro Bio, Inc.) - Operatsion marja|Sotuvning operatsion rentabelligi Editas EDIT|Operatsion marja SLN|ProQR Therapeutics - Operatsion foyda bo'yicha sotuv rentabelligi|Operatsion marja CDXS (Codexis, Inc.)|SGMO: Operatsion foyda bo'yicha sotuv rentabelligi|Nautilus Biotechnology - Operatsion marja|Operatsion foyda normasi MGX (Metagenomi, Inc)|DTIL: Operatsion marja|GBIO: Operatsion foyda koeffitsiyenti|Operatsion rentabellik Boundless Bio Inc.|Sotuvning operatsion marjasi Exicure (XCUR)|Operatsion marja IMNN|PHIO (Phio Pharmaceuticals Corp.) - Operatsion foyda normasi|Mustang Bio, Inc. - Sotuvning operatsion marjasi|RNAZ - Sotuvning operatsion marjasi|BNGO: Sotuvning operatsion marjasi|APDN (Applied DNA Sciences Inc) - Operatsion foyda bo'yicha sotuv rentabelligi|BLUE (Bluebird Bio) - Sotuvning operatsion marjasi|ImmunoPrecise Antibodies Ltd - Operatsion foyda normasi|OMGA (Omega Therapeutics Inc) - Operatsion marja|Operatsion rentabellik OMIC|Operatsion rentabellik Regulus Therapeutics Inc. (RGLS)|Sotuvning operatsion marjasi Syros Pharmaceuticals, Inc. SYRS|Telesis Bio - Sotuvning operatsion marjasi|Operatsion foyda normasi TCON|UBX - Operatsion rentabellik